NCT07376278 Predictors of Clinical Outcomes of Deep Brain Stimulation in Parkinson's Disease
| NCT ID | NCT07376278 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hong Kong University of Science and Technology |
| Condition | Deep Brain Stimulation |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-02-05 |
| Primary Completion | 2036-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2026-02-05 with a primary completion date of 2036-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to identify factors in blood that are associated with response to deep brain stimulation (DBS) surgery in patients with Parkinson's disease. The main questions it aims to answer are: 1. What factors in blood (proteins and RNA) are associated with good vs poor response to DBS? 2. Are these factors able to predict response to DBS? 3. How do these factors change before and after DBS? Blood and leftover brain tissue (which spontaneously adhere to the surgical instruments) will be taken and routine clinical data (including scores from routine assessments) will be collected from consenting participants who undergo DBS.
Eligibility Criteria
Inclusion Criteria: 1. Diagnosis of "Clinically Established PD" as defined by the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease (MDS-PD criteria) 2. Referred for DBS according to standard local clinical guidelines 2a. Significant motor complications despite optimized pharmacological treatment 2ai. UPDRS motor score \>30/108 in the off-medication state 2aii. Hoehn and Yahr staging \>2.5/5 in the off-medication state 2b. Dopamine responsive 2bi. \>33% improvement in UPDRS motor score after levodopa administration 2c. Age ≤75 years 2d. No contraindication to surgery or other significant comorbidity with limited life expectancy 2e. No significant psychiatric problems or cognitive impairment 2f. No structural lesions or features suggestive of atypical parkinsonism or other mimickers of idiopathic PD on neuroimaging Exclusion Criteria: 1. Unwilling to undergo blood sampling for study purposes 2. Evidence of Parkinsonism due to heavy metal exposure 3. History of neurodevelopmental disorder, neurodegenerative disease other than PD, CNS infection, neuroinflammatory disease (e.g. multiple sclerosis, CNS lupus), malignancy within the last 10 years, cerebrovascular accident, HIV infection, systemic autoimmune disease, alcohol dependence or other substance use 4. Unable to pass DBS pre-operative assessment or unwilling to undergo DBS
Contact & Investigator
Nancy Ip
PRINCIPAL INVESTIGATOR
The Hong Kong University of Science and Technology
Frequently Asked Questions
Who can join the NCT07376278 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Deep Brain Stimulation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07376278 currently recruiting?
Yes, NCT07376278 is actively recruiting participants. Contact the research team at boip@ust.hk for enrollment information.
Where is the NCT07376278 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT07376278 clinical trial?
NCT07376278 is sponsored by Hong Kong University of Science and Technology. The principal investigator is Nancy Ip at The Hong Kong University of Science and Technology. The trial plans to enroll 30 participants.